Sign in / Sign up

← Back to investors

Capital Group

投资主体（类型未细分）

Verified investment lower bound≥$10.03M

Investment cases3

Manager operating history—

Representative investments

Anthropic$965B Legora$8.8B Insilico Medicine（英矽智能）$2.65B

Search

#	Company	Market cap / valuationUSD	Total fundingUSD	Last financing / listing	Key investors
01	Anthropic美国	$965BPrivate valuation2026-05-28 Sources · 1 Anthropic raises $65B Series H at $965B valuation \ Anthropic ↗2026-10-22	≥$108.45BVerified lower bound	$65BSeries H2026-05-28 Sources · 1 Anthropic raises $65B Series H at $965B valuation \ Anthropic ↗2026-10-22	Altimeter Capital Dragoneer Investment Group Greenoaks Capital Sequoia Capital Capital Group Coatue Management Other investors · 52 D1 Capital GIC ICONIQ Capital XN D.E. Shaw Ventures Founders Fund MGX Fidelity Investments Lightspeed Venture Partners Spark Capital Amazon Baillie Gifford Blackstone General Catalyst Insight Partners Jane Street T. Rowe Price AMP PBC NX1 Temasek Brookfield DST Global NTTVC Micron Samsung SK Hynix BlackRock D1 Goldman Sachs Alternatives Qatar Investment Authority TPG Accel Addition Alpha Wave Appaloosa Bessemer Venture Partners JPMorgan Menlo Ventures Morgan Stanley Investment Management Sands TowerBrook Whale Rock ARK Invest General Atlantic Ontario Teachers WCM Google SK Telecom Salesforce Ventures Sound Ventures Zoom Ventures LG Technology Ventures
26	Legora瑞典/美国	$8.8BPrivate valuation2026-10-21 Sources · 1 Legora raises $550 million Series E at $8.8 billion valuation to accelerate growth - Legora ↗2026-10-22	≥$1.1BVerified lower bound	$550MSeries E2026-10-21 Sources · 1 Legora raises $550 million Series E at $8.8 billion valuation to accelerate growth - Legora ↗2026-10-22	Atreides Management Baron Capital Capital Group Fidelity Investments Glade Brook J.P. Morgan Other investors · 10 Accel Benchmark Bessemer Venture Partners General Catalyst ICONIQ Capital Insight Partners Menlo Ventures Redpoint Ventures Salesforce Ventures Sands
55	Insilico Medicine（英矽智能）3696.HK · 美国/中国	$2.65BMarket capitalizationMarket date not provided Sources · 1 Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO ↗2026-10-22	≥$110MVerified lower bound	IPO / listing2025-12-30	Value Partners PE Fund Eli Lilly Tencent Oaktree Capital Management Schroders（施罗德） Temasek Other investors · 14 UBS China Asset Management（华夏基金） Pacific Asset Management（太平洋资产） CPIC Investment Management HK E Fund Management（易方达基金） Fullgoal Fund Management（富国基金） Harvest Global Investments（嘉实国际） Taikang Life Insurance（泰康人寿） RTW Investments Exome Asset Management Infini Capital Management（无极资本） Capital Group Mirae Asset Securities Co., Ltd. OrbiMed Advisors IV Limited